CME/CE POSTTEST

Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.

Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.

A review finds vertigo is an underrecognized sign of multiple sclerosis (MS) relapse and that the HINTS exam cannot distinguish an MS attack from stroke.

Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.

Youths with depression had about twice the odds of prescription drug misuse and 4 times the odds of use disorder, compared with peers without depression.

University of Virginia Health is tracking efgartigimod durability in generalized myasthenia gravis and how pharmacists help patients get past barriers.

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.

KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.